経皮ドラッグデリバリーシステムの世界市場：2023-2030年

世界の経皮ドラッグデリバリーシステム市場は、予測期間中（2023-2030年）にCAGR 6.5％で成長すると予測されています。経皮ドラッグデリバリーシステム（TDDS）は、薬物を一定の速度で制御された皮膚から送達する、コントロールドドラッグデリバリーに分類されるシステムです。これらのシステムは、心血管障害や中枢神経障害など様々な疾患の治療に使用されます。最近、FDAは2023年4月に文書を更新し、患者の皮膚に付着すると予想されるTDS製品の表面積を測定する際にスポンサーが考慮すべき適切な方法と、そのデータを統計的に分析する方法を明確にしました。そのためFDAは、ジェネリック経皮・局所デリバリーシステムのガイダンスを更新しました。FDAは、経皮および局所デリバリーシステム（TDS）を使用するジェネリック医薬品の申請に関する2つのガイダンスの改訂案を発表しました。改訂されたガイダンスでは、新薬承認申請（ANDA）スポンサーが市販前申請の際に考慮すべき技術的な明確化が数多くなされています。

セグメント別の見通し

疼痛管理サブセグメントが経皮ドラッグデリバリーシステムの世界市場で大きなシェアを占めると予測される

用途別では、疼痛管理サブセグメントが経皮ドラッグデリバリーシステムの世界市場でかなりのシェアを占めると予想されます。痛みを伴わない薬物投与に対する患者の嗜好の高まりにより、薬物を投与する粘着性皮膚パッチの採用率が大幅に上昇しており、同市場は高成長の可能性を秘めていると予想されます。そのため、企業はこの分野への参入と改良に注力しています。例えば、2023年6月、Innocan Pharma Corporationは、米国特許商標庁（USPTO）への最新の特許出願を発表しました。この動きは、当社の特徴的な大麻とマグネシウムを組み合わせた局所鎮痛技術の幅を広げるという継続的な戦略に沿ったものです。

地域的展望

経皮ドラッグデリバリーシステムの世界市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、その他アジア太平洋地域（中東とアフリカ、その他ラテンアメリカ）を含む地域別にさらに細分化されます。なかでも欧州は、ドイツ、英国、ロシアなどの国々に先進的なヘルスケアインフラ施設が存在することから、世界市場で突出したシェアを占めると予想されています。

北米地域は経皮ドラッグデリバリーシステムの世界市場で大きなCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、同地域における標的疾患（慢性疼痛、中枢神経系疾患、心血管疾患など）の有病率の上昇、経皮ドラッグデリバリーシステムに関連する研究活動の増加に起因しています。したがって、経皮ドラッグデリバリーシステム市場のソリューションの採用に向けて、国のかなりのシフトがあります。例えば、2023年4月、ディフジェン・ファーマシューティカルズLLCは、経皮デリバリーシステム（TDS）と経口溶解性フィルム（ODF）の完全統合開発・製造企業であるアベバ・ドラッグ・デリバリー・サービス社を買収したと発表しました。この戦略的投資により、当社は複雑な剤形を提供する研究開発・製造能力を拡大し、米国に製造拠点を置くことで、貴重なパートナーに確実な供給を行うことができます。最も重要なことは、最高品質で安定した供給により、患者さんに救命薬を手頃な価格で提供することです」。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• 3M Company
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Johnson & Johnson
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Skyepharma Production SAS
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 経皮ドラッグデリバリーシステムの世界市場：タイプ別
  • パッチ
  • ゲル
• 経皮ドラッグデリバリーシステムの世界市場：用途別
  • 高血圧
  • 乗り物酔い
  • 疼痛管理
  • その他（+感染、ホルモン、呼吸器、代謝）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• 4P Therapeutics, LLC
• Altaris
• Bayer AG
• Biogel Technology, Inc.
• Boehringer Ingelheim GmbH
• Echo Therapeutics, Inc.
• GlaxoSmithKline plc
• Hisamitsu Pharmaceutical Co. Inc.
• Mylan Pharmaceuticals, Inc.
• Novartis AG
• Noven Pharmaceuticals, Inc.
• Purdue Pharma L.P.
• Transdermal Technologies, Inc.
• Viatris Inc.
• Watson Pharmaceuticals, Inc.

LIST OF TABLES

• 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 2. GLOBAL TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
• 3. GLOBAL TRANSDERMAL GEL MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR HYPERTENSION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
• 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR MOTION SICKNESS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
• 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR PAIN MANAGEMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
• 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR OTHERS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
• 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 10. NORTH AMERICAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 12. NORTH AMERICAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 13. EUROPEAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 14. EUROPEAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 15. EUROPEAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 16. ASIA- PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 17. ASIA- PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 18. ASIA- PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
• 19. REST OF THE WORLD TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 21. REST OF THE WORLD TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
• 2. GLOBAL TRANSDERMAL PATCHES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL TRANSDERMAL GEL MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
• 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR HYPERTENSION MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR MOTION SICKNESS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR PAIN MANAGEMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS FOR OTHERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. US TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 11. CANADA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 12. UK TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 13. FRANCE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 14. GERMANY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 15. ITALY TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 16. SPAIN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 17. REST OF EUROPE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 18. INDIA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 19. CHINA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 20. JAPAN TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 21. SOUTH KOREA TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 22. REST OF ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)
• 23. REST OF THE WORLD TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2022-2030 ($ MILLION)

Title: Global Transdermal Drug Delivery Systems Market Size, Share & Trends Analysis Report by Type (Patches and gel), by Application (Hypertension, Motion Sickness, Pain Management and Others),Forecast Period (2023-2030).

The global transdermal drug delivery systems market is anticipated to grow at a CAGR of 6.5% during the forecast period (2023-2030). Transdermal drug delivery system (TDDS) is the systems categorized under the controlled drug delivery, where drugs are delivered through the skin at a fixed and controlled rate. These systems are used for treating various disease conditions such as cardiovascular disorders, and central nervous system disorders, etc. Recently in April 2023, FDA updated the documents to clarify the appropriate methods sponsors should consider while measuring the surface area of the TDS product that is expected to adhere to a patient's skin and how to statistically analyze that data. That why FDA updates generic transdermal and topical delivery systems guidance's. It issued two revised draft guidance for generic drug submissions that use transdermal and topical delivery systems (TDS). The revised guidance make numerous technical clarifications that abbreviated new drug application (ANDA) sponsors should consider when filing their premarket application.

Segmental Outlook

The global transdermal drug delivery systems market is segmented on the type and application. Based on the type, the market is sub-segmented into patches and gel. Based on the application, the market is sub-segmented into hypertension, motion sickness, pain management and others. Among the type, the patches sub-segment is anticipated to hold a considerable share of the market. Owing to its use in pain management, which is boosting the market growth. And the increasing cases of cancer, lead accelerated embracing of pain patches.

The Pain Management Sub-Segment is Anticipated to Hold a Considerable Share of the Global Transdermal Drug Delivery Systems Market

Among the application, the Pain management sub-segment is expected to hold a considerable share of the global transdermal drug delivery system market. The rising patient preference for pain-free drug administration has led to a significant surge in the adoption rate of adhesive skin patches that administer drugs, which is anticipated to present the market with high growth potential. Hence Companies are focusing to enter and improve in this segment. For an instance, in June 2023, Innocan Pharma Corporation has announced the filing of its most recent patent application to the United States Patent and Trademark Office (USPTO). This move is in line with the Company's ongoing strategy to expand the breadth of its distinctive combined Cannabis and Magnesium topical pain-relief technology.

Regional Outlook

The global transdermal drug delivery systems market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to presence of advanced healthcare infrastructure facilities in countries like Germany, UK and Russia.

The North America Region is Expected to Grow at a Significant CAGR in the Global Transdermal Drug Delivery Systems Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the region is driven by the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, and the increasing number of research activities related to transdermal drug delivery systems. Hence, there is considerable shift of the country towards the adoption of the Transdermal Drug Delivery Systems market solutions. For an instance in April 2023, DifGen Pharmaceuticals LLC announced that it has acquired Aveva Drug Delivery Services Inc. a fully integrated developer and manufacturer of Transdermal Delivery Systems (TDS) and Oral Dissolvable Films (ODF). This strategic investment allows us to expand our R&D & manufacturing capabilities in offering complex dosage forms and secure supply to our valuable partners with local US based manufacturing. Most importantly, it will provide patients affordable lifesaving medication with highest quality and consistent supply".

Market Players Outlook

The major companies serving the transdermal drug delivery systems market includes Boehringer Ingelheim GmbH, Echo Therapeutics Inc., GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Mylan Pharmaceuticals, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Kyung Hee signed a new technology transfer agreement with Dasan Pharmaceutical for a pioneering transdermal drug delivery material technology that incorporates a novel polymer compound developed by Professor Dokyoung Kim of the College of Medicine.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global transdermal drug delivery systems market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. 3M Company
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Johnson & Johnson
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Skyepharma Production SAS
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Transdermal Drug Delivery Systems Market by Type
  • 4.1.1. Patches
  • 4.1.2. Gel
• 4.2. Global Transdermal Drug Delivery Systems Market by Application
  • 4.2.1. Hypertension
  • 4.2.2. Motion Sickness
  • 4.2.3. Pain Management
  • 4.2.4. Others (+Infection, Hormone, Respiratory and Metabolic)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. 4P Therapeutics, LLC
• 6.2. Altaris
• 6.3. Bayer AG
• 6.4. Biogel Technology, Inc.
• 6.5. Boehringer Ingelheim GmbH
• 6.6. Echo Therapeutics, Inc.
• 6.7. GlaxoSmithKline plc
• 6.8. Hisamitsu Pharmaceutical Co. Inc.
• 6.9. Mylan Pharmaceuticals, Inc.
• 6.10. Novartis AG
• 6.11. Noven Pharmaceuticals, Inc.
• 6.12. Purdue Pharma L.P.
• 6.13. Transdermal Technologies, Inc.
• 6.14. Viatris Inc.
• 6.15. Watson Pharmaceuticals, Inc.